Randall Lee, MD

Randall A. Lee, MD

Assistant Professor, Department of Urology

Specialties

  • Urology

Areas of Expertise

Ureteral Cancer, Kidney Cancer, Testicular Cancer, Bladder Cancer, Penile Cancer, Urethral Cancer, Adrenal Tumor, Prostate Cancer

Treatment Focus

Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery

Prostate Cancer: active surveillance, focal therapy, robotic radical nerve-sparing prostatectomy, prior radiation therapy (salvage prostatectomy)

Bladder Cancer: robotic cystoprostatectomy, cystectomy or anterior exenteration with extended template pelvic lymph node dissection, completely intracorporeal (no open incision) creation of urinary diversion (ileal conduit and neobladder reconstruction), prior radiation therapy (salvage cystectomy)

Kidney Cancer: kidney-sparing partial nephrectomy and radical nephrectomy, Patients with previous kidney surgery

Adrenal masses: minimally-invasive adrenal surgery 

Robotic removal of non-cancerous (benign), enlarged prostate (simple prostatectomy): Patients with large prostate glands (>100 grams), Patients with catheter dependent urinary retention, Patients with large bladder diverticulum

Minimally invasive robotic reconstruction of the kidney, ureter and bladder
 

Distinctions

Treatment Philosophy

As a highly skilled urologist with specialized training in minimally invasive robotic surgery, I am dedicated to providing comprehensive and compassionate care to patients diagnosed with urologic cancers, particularly prostate, kidney, and bladder cancer. My treatment philosophy revolves around utilizing cutting-edge techniques, evidence-based practices, and personalized approaches to deliver the best possible outcomes for each individual patient.

Patient-Centered Care: At the heart of my philosophy is a patient-centered approach. I firmly believe that every patient is unique, and their treatment plan should reflect their specific medical history, lifestyle, preferences, and goals. I strive to form strong doctor-patient relationships built on trust, empathy, and open communication. Understanding each patient's concerns and expectations is paramount in guiding them towards the most appropriate treatment choice. 

Having access to advanced treatment modalities, I believe in presenting my patients with a range of options tailored to their specific condition. These may include active surveillance, robotic-assisted surgery, radiation therapy, immunotherapy, and targeted therapies. By thoroughly explaining the potential benefits and risks of each option, I empower my patients to make informed decisions about their care.

Minimally Invasive Robotic Surgery Expertise: My training at University of Southern California’s prestigious minimally invasive robotic surgery program, has provided me with invaluable expertise in performing complex urologic cancer surgeries. I am dedicated to employing the latest advancements in robotic-assisted procedures, which offer numerous benefits to patients, including reduced postoperative pain, quicker recovery, and improved surgical precision.

Collaborative Care: I strongly advocate for a multidisciplinary approach to urologic cancer treatment. Collaborating with a team of experienced specialists, including medical oncologists, radiation oncologists, pathologists, and other healthcare professionals, allows us to devise comprehensive treatment plans that address all aspects of a patient's well-being.

Continual Learning and Research: As a committed urologist, I remain devoted to ongoing professional development and keeping up-to-date with the latest advancements and treatment options. I actively participate in clinical trials and research studies to contribute to the field's progress and offer my patients access to promising novel therapies when appropriate.

Support and Empowerment: Throughout the treatment journey, I am dedicated to providing unwavering support to my patients and their families. Cancer can be emotionally challenging, and I aim to empower my patients by offering them the knowledge and resources they need to cope with their diagnosis, treatment, and survivorship.

My treatment philosophy revolves around patient-centered care, cutting-edge technology, personalized treatment plans, and a collaborative approach. By integrating my expertise in minimally invasive robotic surgery and my dedication to providing the best possible care, I aim to improve the lives of my patients while striving for excellence in the field of urologic oncology
 

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427
  • Fox Chase Cancer Center - Huntingdon Pike
    8 Huntingdon Pike
    Rockledge, PA 19046
    Phone: 888-369-2427
  • Fox Chase Cancer Center - Chestnut Hill
    8835 Germantown Avenue
    Philadelphia, PA 19118
    Phone: 888-369-2427
  • Fox Chase Cancer Center - Voorhees
    502 Centennial Blvd
    Suite 7
    Voorhees, NJ 08043
    Phone: 888-369-2427

Educational Background

UNIVERSITY OF SOUTHERN CALIFORNIA – KECK SCHOOL OF MEDICINE

  • Robotic Urologic Oncology & Minimally Invasive Surgery Fellowship 07/2022 –6/2023

TEMPLE UNIVERSITY HOSPTIAL

  • General Surgery Internship 06/2017 – 06/2018
  • Urology Residency 07/2018 – 06/2022

DREXEL UNIVERSITY, COLLEGE OF MEDICINE

  • Doctor of Medicine 08/2013 – 06/2017

DREXEL UNIVERSITY, COLLEGE OF ARTS AND SCIENCES

Bachelor of Science in Biological Sciences 09/2008 – 06/2012

  • Magna Cum Laude
  • Dean’s List Freshman, Sophomore, Junior, and Senior Year
  • Drexel Scholar Athlete Freshman, Sophomore, Junior, and Senior Year
  • Named to the 2011 & 2012 Academic All-Area Team in athletics

Certifications

  • American Board of Urology

Memberships

  • American Urological Association
  • Philadelphia Urological Society
  • Alpha Omega Alpha Honors Society
  • Gold Humanism Honors Society

     

Research Interests

Cancer survivorship; Development of technologies and innovative techniques to optimize treatment outcomes and minimize side effects.

Selected Publications

MyNCBI

Additional Publications

 

  • Lee RA, Eun DD. “Robotic Partial Nephrectomy (Transperitoneal Approach).” Robotic UrologicSurgery: Clinical Practice and Case Analysis, edited by Gongxian Wang, World Publishing Xi'an Co., Ltd., 2022, pp. 29–33.
  • Lee RA, Eun DD. “Robotic Simple Prostatectomy.” Robotic Urologic Surgery: Clinical Practice and Case Analysis, edited by Gongxian Wang, World Publishing Xi'an Co., Ltd., 2022, pp. 221–224.
  • Carrion A, Hussein AA, Eun DD, Hosseini A, Gaya JM, Abaza R, Bonet X, Iqbal U, Lee RA, Lee Z, Lee M, Raventos C, Moreno O, Palou J, Breda A, Lozano F, Vigues F, Trilla E, Guru K. Perioperative and functional outcomes of robot-assisted ureteroenteric reimplantation: A multicenter study of seven referral institutions. European Urology. January 2022
  • Yang KY, Asghar AM, Lee RA, Strauss D, Kuppa S, Lee Z, Metro M, Eun DD. Robot-assisted laparoscopic distalureteroureterostomy for distal benign ureteral strictures with long-term follow up. J of Endourology. 2021
  • Lee M, Lee Z, Strauss D, Koster H, Jun M, Asghar AM, Lee RA, Strauss D, Patel N, Kim D, Komaravolu S, Drain A, Metro MJ, Zhao L, Stifelman M, Eun DD. Intermediate-term Outcomes After Robotic Ureteral Reconstruction for Long-Segment (≥4 centimeters) Strictures in the Proximal Ureter: A Multi-institutional Experience. Investigative and Clinical Urology. January 2021.
  • Strauss DM, Lee RA, Maffucci F, Abbott D, Masic S, Kutikov A. The future of “Retro” robotic partial nephrectomy.Translational Andrology and Urology. May 2021.
  • Lee Z, Lee M, Koster H, Lee R, Cheng N, Jun M, Slawin J, Zhao LC, Stifelman MD, Eun DD. A multi-institutional experience with robotic ureteroplasty with buccal mucosa graft: An updated analysis of intermediate-term outcomes. Urology. January 2021.
  • Lee M, Lee Z, Strauss D, Jun MS, Koster H, Asghar AM, Lee R, Chao B, Cheng N, Ahmed M, Lovallo G, Munver R, Zhao LC, Stifelman MD, Eun DD. Multi-institutional experience comparing outcomes of adult patients undergoing secondary versus primary robotic pyeloplasty. Urology. 2020
  • Asghar A, Lee Z, Lee RA, Slawin J, Cheng N, Koster H, Strauss DM, Lee M, Reddy R, Drain A, Lama-Tamang T, Jun MS, Metro M, Ahmed M, Stifelman MD, Zhao L, Eun D. Robotic Ureteral Reconstruction in Patients with Radiation-Induced Ureteral Strictures: Experience from the Collaborative of Reconstructive Robotic Ureteral Surgery (CORRUS). J of Endourology. 2020.
  • Masic S, Srivastava A, Kloth D, Needleman R, Bloom E, Uzzo RN, Amoroso C, Lee RA, Greenberg R, Smaldone M, Viterbo R, Joshi S, Chen DY, Uzzo RG, Kutikov A. Bacillus Calmette-Guerin (BCG) Packaged for Percutaneous Vaccination Can Be Safely Used for Intravesical Instillation in Patients with Urothelial Carcinoma of the Bladder. Urology Practice. 2020.
  • Asghar A, Lee RA, Yang KY, Metro M, Eun DD. Robot-assisted distal ureteral reconstruction for benign pathology: Current state. IC Urology. 2020
  • Lee RA, Kutikov A, and Uzzo RG. Robotic Nephron Sparing Surgery for High Complexity Renal Tumors. AUANews. March 2019.
  • Ristau BT, Lee RA, Kutikov A. Retroperitoneoscopic Robot-Assisted Partial Nephrectomy on a Morbidly Obese Patient with Tumor in the Upper Pole. EAU Surgery in Motion. 2017.
  • Fuletra J, Ristau B, Milestone B, Cooper HS, Movva S, Galloway TJ, Lee R, Waingankar N, Kutikov A. Angiosarcoma of the Adrenal Gland Treated Using a Multimodal Approach. Urology Case Reports. 2016.
  • Hoosain J, Fisher P, McCaffrey J, Lee R, Hasni S, and Andrew Kohut. “The use of contrast echocardiography to identify infiltrating lymphoma in the myocardium.” International Journal of Clinical and Medical Imaging. 2015
  • Terry NA, Lee R, Walp E, Kaestner K, and Catherine Lee May. “Dysgenesis of enteroendocrine cells in Aristaless-Related Homeobox polyalanine expansion mutations.” Journal of Pediatric Gastroenterology and Nutrition. 2015.
  • Vorobyeva A, Lee R, Miller S, Longen C, Sharoni M, Kandelwal PJ, Kim F, Marenda D, Aleister J. Saunders. “Cyclopamine modulates gamma-secretase-mediated cleavage of amyloid precursor protein by altering its subcellular trafficking and lysosomal degradation.” Journal of Biological Chemistry. 2014.
  • Terry NA, Walp E, Lee R, Kaestner K, and Catherine Lee May. "Impaired enteroendocrine development in intestinal-specific Islet1 mouse mutants causes impaired glucose homeostasis." American Journal of Physiology-Gastrointestinal and Liver Physiology. 2014.
  • Wilcox C, Terry NA, Walp E, Lee R, Catherine Lee May. “Temporal requirement of Arx in maintaining islet alphacell fate.” PLOSONE. 2013.

Related Articles